Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Frechen – page 13

1 443 clinical trials in Frechen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frechen at a glance
1 443
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 443 trials in Frechen

Open in trial search

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enicepatide
  • Sponsor:F. Hoffmann-La Roche AG

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Neoplasm

Recruiting

Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

FWY003 in Geographic Atrophy Secondary to Age-Related Macular Degeneration in Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:FWY003 tosilate
  • Sponsor:Novartis Pharma AG

Stomatitis+1

Recruiting

A study to compare the effectiveness of bupivacaine hydrochloride monohydrate and lidocaine hydrochloride for treating mouth sores in patients with head and neck cancer.

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bupivacaine hydrochloride monohydrate
  • Sponsor:OncoZenge AB

A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Potassium Chloride
  • Sponsor:Dyne Therapeutics Inc.

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Novartis Pharma AG

A study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the safety and effectiveness of QEL-005 in patients with diffuse cutaneous systemic sclerosis and difficult to treat rheumatoid arthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:QEL-005
  • Sponsor:Quell Therapeutics Limited

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Frechen

What the registry says about research in the country

01 Hematologic Oncology

Clinical research focusing on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), evaluating new combination therapies with venetoclax and comparing different treatment durations based on measurable residual disease.

  • Treatment Duration Optimization
  • Combination Therapy Assessment
  • Disease Progression Monitoring

Innovative approaches in blood cancer treatment aimed at improving patient outcomes through personalized therapy duration.

02 Supportive Cancer Care

Investigation into preventing and managing chemotherapy-induced polyneuropathy (CIPN) using Aconite Pain Oil, with a focus on improving quality of life for cancer patients undergoing chemotherapy treatment.

  • Neuropathy Prevention
  • Symptom Management
  • Quality of Life Enhancement

Novel approaches to reducing chemotherapy side effects and maintaining treatment effectiveness.

03 Precision Medicine

Advanced research incorporating artificial intelligence to evaluate treatment resistance in patients with polycythemia vera, focusing on predicting hydroxyurea resistance patterns.

  • AI-Based Prediction Models
  • Treatment Resistance Analysis
  • Personalized Treatment Strategies

Integration of machine learning with clinical practice to optimize treatment selection and patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.